The neoadjuvant PAMELA trial (SOLTI-1114)15 treated 151 patients with HER2+ BC with trastuzumab and lapatinib (and endocrine therapy if the tumour was hormone receptor [HR] positive) for 18 weeks. This evidence concerns the gene ERBB2 and breast cancer.